Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc senior vice president and general counsel John Adam Zangerle reported a routine share withholding related to restricted stock vesting. On June 1, 2026, 337 ordinary shares were withheld from 1,157 vested restricted shares to cover tax obligations, based on the NYSE closing price that day.
After this tax-withholding disposition, he directly owned 33,332 ordinary shares, including 7,354 restricted shares as of June 1, 2026. The restrictions on these ordinary shares are scheduled to lapse in tranches through June 5, 2028.
STERIS plc vice president and corporate treasurer Renato Tamaro reported a routine tax-withholding share disposition related to vesting equity awards. On June 1, 2026, 81 ordinary shares were withheld from 241 restricted shares that vested to cover required employment and tax obligations, valued at the NYSE closing market price that day.
After this non-market transaction, Tamaro directly held 5,614 ordinary shares, including 1,234 restricted shares as of June 1, 2026. The filing also outlines the schedule on which these remaining restricted shares are set to lapse over 2026–2028.
STERIS plc executive Lindsey McGowan reported routine share updates related to vesting of restricted stock and associated tax withholding. On June 1, 2026, 660 restricted shares vested, and 198 of those shares were withheld to cover taxes, a non-market "F" code tax-withholding disposition.
After these transactions, McGowan directly holds 4,830 ordinary shares, including 3,090 restricted shares subject to future vesting through January 2, 2029. In addition, 255 ordinary share equivalent units are held on her behalf in the STERIS Corporation 401(k) Plan. No open-market purchases or sales were reported.
STERIS plc senior executive Cary L. Majors reported routine equity compensation activity. On June 1, 2026, 2,697 restricted ordinary shares vested, and 768 of those shares were withheld to cover tax obligations, reflected as a tax-withholding disposition rather than an open-market sale.
After this event, Majors directly held 12,659 ordinary shares, including 7,441 restricted shares as of June 1, 2026, with restrictions scheduled to lapse in tranches through 2028. In addition, units representing 67 ordinary share equivalents were held for Majors under the STERIS Corporation 401(k) Plan.
STERIS plc senior executive Julia Madsen reported a routine tax-withholding share disposition tied to vesting equity compensation. On June 1, 2026, 578 restricted shares vested, and 208 of those shares were withheld to cover required taxes based on the NYSE closing market price that day.
After this transaction, she directly holds 10,502 ordinary shares, including 3,425 restricted shares. The restrictions on these ordinary shares are scheduled to lapse in tranches between June 2026 and June 2028.
STERIS plc senior executive reports routine tax withholding on vested shares. On June 1, 2026, SVP & GM, AST Kenneth E. Kohler had 109 ordinary shares withheld to cover taxes on 373 restricted shares that vested, with the value based on the NYSE closing price on that date.
After this disposition, he directly holds 9,533 ordinary shares, of which 3,141 are still restricted as of June 1, 2026 and scheduled to lapse in stages through June 5, 2028. The filing also corrects previously misreported beneficial ownership amounts.
STERIS plc SVP & Chief HRO Mary Clare Fraser reported a routine tax-withholding share disposition. On June 1, 2026, 2,313 restricted shares vested, and 673 ordinary shares were withheld to cover taxes based on the NYSE closing market price that day. After this withholding, she directly holds 12,209 ordinary shares. As of June 1, 2026, 6,573 of these shares remain restricted, with restrictions scheduled to lapse in several tranches through June 5, 2028.
STERIS plc President and CEO Daniel A. Carestio reported a routine tax-related share disposition. On June 1, 2026, 1,254 ordinary shares were withheld from 4,308 restricted shares that vested, to cover taxes determined under applicable laws at the NYSE closing market price.
After this withholding, Carestio directly holds 49,842 ordinary shares. As of June 1, 2026, 28,746 of these are restricted shares scheduled to lapse over several dates through June 5, 2028, reflecting ongoing equity-based compensation rather than an open-market sale.
STERIS plc reported that Sr. Vice President and CFO Karen L. Burton had 99 ordinary shares withheld on June 1, 2026 to cover tax obligations on vested restricted stock. The Form 4 classifies this as a tax-withholding disposition, not an open-market trade.
The 99 shares were withheld from 340 restricted shares that vested on that date, valued at the NYSE closing market price. After this transaction, Burton directly holds 8,205 ordinary shares, of which 5,139 are restricted with scheduled lapses through October 1, 2028.